SeeThruEquity Initiates Research Coverage on NanoViricides, Inc.
March 27 2014 - 9:00AM
Business Wire
SeeThruEquity, a leading independent equity research and
corporate access firm focused on smallcap and microcap public
companies, today announced that it has initiated coverage on
NanoViricides, Inc. (NYSE-MKT:NNVC), a development stage company
that is creating special purpose nanomaterials for viral
therapy.
“Unlike a typical emerging biotechnology company with one, or
maybe two, lead drug candidates with blockbuster market potential,
NanoViricides can use their technology to target numerous drug
categories. They are initially developing Injectable FluCide™ for
hospitalized patients being treated for all influenzas. This
represents a $25bn annual market opportunity,” remarked Ajay
Tandon, CEO of SeeThruEquity. “We are initiating coverage with a
fair value estimate of $7.21 per share.”
The note is available to SeeThruEquity Select Members on
SeeThruEquity's website and can be directly accessed here: NNVC
Initiation Report. SeeThruEquity is an approved equity research
contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s.
The note will also be available on these platforms.
Please review important disclosures on our website at
www.seethruequity.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm
focused on companies with less than $1 billion in market
capitalization. The research is not paid for and unbiased. We
do not conduct any investment banking or commission based business.
We are approved to contribute our research to Thomson One Analytics
(First Call), Capital IQ, FactSet, Zacks and distribute our
research to our database of opt-in investors. We also contribute
our estimates to Thomson Estimates, the leading estimates platform
on Wall Street.
For more information visit www.seethruequity.com.
About NanoViricides, Inc.
NanoViricides is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others. For more information, please
go to www.NanoViricides.com.
SeeThruEquityAjay Tandon, 646-495-0939
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024